Carlo Pozzilli
#146,968
Most Influential Person Now
Researcher
Carlo Pozzilli's AcademicInfluence.com Rankings
Carlo Pozzillibiology Degrees
Biology
#10724
World Rank
#14077
Historical Rank
Endocrinology
#146
World Rank
#158
Historical Rank
Neuroscience
#1684
World Rank
#1736
Historical Rank
Download Badge
Biology
Carlo Pozzilli's Degrees
- PhD Neuroscience University of Oxford
Why Is Carlo Pozzilli Influential?
(Suggest an Edit or Addition)Carlo Pozzilli's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Defining the clinical course of multiple sclerosis (2014) (2372)
- Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. (1981) (626)
- Induction of a non-encephalitogenic type 2 T helper-cell autoimmune response in multiple sclerosis after administration of an altered peptide ligand in a placebo-controlled, randomized phase II trial (2000) (499)
- REGIONAL CEREBRAL OXYGEN SUPPLY AND UTILIZATION IN DEMENTIAA CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN-15 AND POSITRON TOMOGRAPHY A CLINICAL AND PHYSIOLOGICAL STUDY WITH OXYGEN - 15 AND POSITRON TOMOHRAPHY (1981) (436)
- Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring (2007) (391)
- A randomized, double‐blind, placebo‐controlled, parallel‐group, enriched‐design study of nabiximols * (Sativex®), as add‐on therapy, in subjects with refractory spasticity caused by multiple sclerosis (2011) (378)
- Diffusion-Weighted Imaging Tractography-Based Parcellation of the Human Lateral Premotor Cortex Identifies Dorsal and Ventral Subregions with Anatomical and Functional Specializations (2007) (329)
- fMRI evidence of brain reorganization during attention and memory tasks in multiple sclerosis (2004) (301)
- Multiple sclerosis in childhood: clinical features of 149 cases (1997) (294)
- Randomized placebo-controlled trial of mitoxantrone in relapsing-remitting multiple sclerosis: 24-month clinical and MRI outcome (1997) (283)
- Progressing neurological deficit secondary to acute ischemic stroke. A study on predictability, pathogenesis, and prognosis. (1995) (258)
- Assessing walking disability in multiple sclerosis (2012) (240)
- Guidelines on use of anti‐IFN‐β antibody measurements in multiple sclerosis: report of an EFNS Task Force on IFN‐β antibodies in multiple sclerosis (2005) (218)
- Interferon beta-1b in secondary progressive MS (2004) (207)
- The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. European Study Group on Interferon beta-1b in secondary progressive multiple sclerosis. (2000) (203)
- Cognitive and psychosocial features of childhood and juvenile MS (2008) (203)
- Cortical motor reorganization after a single clinical attack of multiple sclerosis. (2002) (182)
- Cognitive and psychosocial features in childhood and juvenile MS (2010) (178)
- Intravenous immunoglobulin in secondary progressive multiple sclerosis: randomised placebo-controlled trial (2004) (177)
- Home-Based Balance Training Using the Wii Balance Board (2013) (164)
- A mechanism-based classification of pain in multiple sclerosis (2012) (157)
- Fatigue in MS is associated with specific clinical features (1995) (151)
- Comparison of the effects of acetyl l-carnitine and amantadine for the treatment of fatigue in multiple sclerosis: results of a pilot, randomised, double-blind, crossover trial (2004) (149)
- Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial (2004) (145)
- Pregnancy and fetal outcomes after interferon-β exposure in multiple sclerosis (2010) (144)
- ‘Gender gap’ in multiple sclerosis: magnetic resonance imaging evidence (2003) (142)
- Prospective study of multiple sclerosis with early onset (2002) (140)
- Sex hormones modulate brain damage in multiple sclerosis: MRI evidence (2005) (139)
- Structural and functional bases for individual differences in motor learning (2011) (139)
- Real‐life impact of early interferonβ therapy in relapsing multiple sclerosis (2009) (139)
- Final analysis of the European multicenter trial on IFNβ-1b in secondary-progressive MS (2001) (138)
- Effects of education level and employment status on HRQoL in early relapsing-remitting multiple sclerosis (2007) (136)
- Imaging of leukocytic infiltration in human cerebral infarcts. (1985) (135)
- Long-term effects of delayed-release dimethyl fumarate in multiple sclerosis: Interim analysis of ENDORSE, a randomized extension study (2016) (130)
- The Diagnostic Accuracy of Static Posturography in Predicting Accidental Falls in People With Multiple Sclerosis (2013) (130)
- Fatigue in progressive multiple sclerosis: results of a randomized, double-blind, placebo-controlled, crossover trial of oral 4-aminopyridine (2001) (130)
- Neutralizing antibodies during treatment of secondary progressive MS with interferon β-1b (2003) (129)
- One‐year MRI scan predicts clinical response to interferon beta in multiple sclerosis (2009) (128)
- Factors affecting course and survival in Alzheimer's disease. A 9-year longitudinal study. (1994) (127)
- Predictive value of brain perfusion single-photon emission computed tomography in acute ischemic stroke. (1990) (127)
- Use of Bacille Calmette-Guèrin (BCG) in multiple sclerosis. (1999) (125)
- A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials. (1998) (124)
- Functional Basis of Memory Impairment in Multiple Sclerosis: A [18F]FDG PET Study (1996) (122)
- Oral ponesimod in relapsing–remitting multiple sclerosis: a randomised phase II trial (2014) (122)
- Spontaneous middle cerebral artery reperfusion in ischemic stroke. A follow-up study with transcranial Doppler. (1995) (120)
- Predictors of long–term clinical response to interferon beta therapy in relapsing multiple sclerosis (2006) (119)
- Brain atrophy in relapsing-remitting multiple sclerosis: relationship with ‘black holes’, disease duration and clinical disability (2000) (112)
- Serial study of gadolinium‐DTPA MRI enhancement in multiple sclerosis (1990) (112)
- Effects of Bacille Calmette-Guérin after the first demyelinating event in the CNS (2014) (110)
- Breastfeeding is not related to postpartum relapses in multiple sclerosis (2011) (110)
- SPECT, MRI and cognitive functions in multiple sclerosis. (1991) (109)
- Early physiotherapy after injection of botulinum toxin increases the beneficial effects on spasticity in patients with multiple sclerosis (2007) (107)
- Magnetic resonance imaging changes with recombinant human interferon-beta-1a: a short term study in relapsing-remitting multiple sclerosis. (1996) (107)
- Multiple sclerosis: altered thalamic resting-state functional connectivity and its effect on cognitive function. (2014) (106)
- CMRO2 and CBF by the oxygen-15 inhalation technique. Results in normal volunteers and cerebrovascular patients. (1981) (104)
- T(1) hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. (2001) (101)
- Fast spin-echo and fast fluid-attenuated inversion-recovery versus conventional spin-echo sequences for MR quantification of multiple sclerosis lesions. (1997) (101)
- Effect of corpus callosum damage on ipsilateral motor activation in patients with multiple sclerosis: A functional and anatomical study (2007) (100)
- Disease-modifying drugs in childhood-juvenile multiple sclerosis: results of an Italian co-operative study (2005) (99)
- Fatigue and magnetic resonance imaging activity in multiple sclerosis (1999) (98)
- Contribution of Corticospinal Tract Damage to Cortical Motor Reorganization after a Single Clinical Attack of Multiple Sclerosis (2002) (97)
- Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis (2009) (97)
- Neuropsychological features in childhood and juvenile multiple sclerosis (2014) (96)
- Gadolinium enhanced MRI predicts clinical and MRI disease activity in relapsing-remitting multiple sclerosis. (1997) (96)
- Home based management in multiple sclerosis: results of a randomised controlled trial (2002) (94)
- Pregnancy and fetal outcomes after Glatiramer Acetate exposure in patients with multiple sclerosis: a prospective observational multicentric study (2012) (93)
- Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis (2012) (91)
- Assessing the Correlation between Grey and White Matter Damage with Motor and Cognitive Impairment in Multiple Sclerosis Patients (2013) (91)
- The relationship between infratentorial lesions, balance deficit and accidental falls in multiple sclerosis (2011) (90)
- Assessing response to interferon-β in a multicenter dataset of patients with MS (2016) (89)
- A longitudinal study of MR diffusion changes in normal appearing white matter of patients with early multiple sclerosis. (2002) (88)
- MRI in multiple sclerosis during the menstrual cycle: Relationship with sex hormone patterns (1999) (87)
- A longitudinal fMRI study on motor activity in patients with multiple sclerosis. (2005) (87)
- Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS (2016) (87)
- Epidural analgesia and cesarean delivery in multiple sclerosis post-partum relapses: the Italian cohort study (2012) (87)
- Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticity (2016) (86)
- Serum MMP-9/TIMP-1 and MMP-2/TIMP-2 ratios in multiple sclerosis: relationships with different magnetic resonance imaging measures of disease activity during IFN-beta-1a treatment (2005) (85)
- Monthly corticosteroids decrease neutralizing antibodies to IFNβ1b: a randomized trial in multiple sclerosis (2002) (84)
- Psychopathological and Cognitive Effects of Therapeutic Cannabinoids in Multiple Sclerosis: A Double-Blind, Placebo Controlled, Crossover Study (2008) (84)
- Anterior Corpus Callosum Atrophy and Verbal Fluency in Multiple Sclerosis (1991) (83)
- The effect of interferon β-1b on quantities derived from MT MRI in secondary progressive MS (2003) (82)
- Enhanced brain motor activity in patients with MS after a single dose of 3,4-diaminopyridine (2004) (81)
- Safety and efficacy of natalizumab in children with multiple sclerosis (2010) (81)
- Development of neutralizing antibodies in patients with relapsing-remitting multiple sclerosis treated with IFN-beta1a. (1998) (80)
- Gray- and white-matter changes 1 year after first clinical episode of multiple sclerosis: MR imaging. (2010) (80)
- Simplified, noninvasive PET measurement of blood-brain barrier permeability. (1987) (79)
- Fingolimod protects cultured cortical neurons against excitotoxic death. (2013) (78)
- The effect of disease activity on leptin, leptin receptor and suppressor of cytokine signalling-3 expression in relapsing–remitting multiple sclerosis (2007) (78)
- Peripheral white blood cell count in cerebral ischemic infarction (1985) (78)
- Multiple sclerosis: changes in microarchitecture of white matter tracts after training with a video game balance board. (2014) (77)
- Ponesimod Compared With Teriflunomide in Patients With Relapsing Multiple Sclerosis in the Active-Comparator Phase 3 OPTIMUM Study: A Randomized Clinical Trial. (2021) (76)
- Involvement of the limbic system in multiple sclerosis patients with depressive disorders (1996) (74)
- Clinically isolated syndrome suggestive of multiple sclerosis: voxelwise regional investigation of white and gray matter. (2010) (74)
- Predominant and stable T cell responses to regions of myelin basic protein can be detected in individual patients with multiple sclerosis (1993) (74)
- Multiple sclerosis: white and gray matter damage associated with balance deficit detected at static posturography. (2013) (74)
- Fatigue and its relationships with cognitive functioning and depression in paediatric multiple sclerosis (2012) (74)
- Blood cholesterol and MRI activity in first clinical episode suggestive of multiple sclerosis (2002) (72)
- A 6‐year clinical and MRI follow‐up study of patients with relapsing–remitting multiple sclerosis treated with Interferon‐beta (2002) (72)
- Acute myeloid leukemia in Italian patients with multiple sclerosis treated with mitoxantrone (2011) (72)
- Fingolimod versus interferon beta/glatiramer acetate after natalizumab suspension in multiple sclerosis. (2015) (72)
- Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs (2014) (71)
- Natalizumab in the pediatric MS population: results of the Italian registry (2015) (70)
- Pregnancy decision-making in women with multiple sclerosis treated with natalizumab (2018) (69)
- Preservation of motor skill learning in patients with multiple sclerosis (2011) (69)
- Relating Brain Damage to Brain Plasticity in Patients With Multiple Sclerosis (2012) (69)
- Long-term results of immunomodulatory treatment in children and adolescents with multiple sclerosis: the Italian experience (2009) (68)
- Unraveling treatment response in multiple sclerosis (2018) (68)
- A dual concurrent mechanism explains trigeminal neuralgia in patients with multiple sclerosis (2016) (68)
- Magnetic resonance outcome of new enhancing lesions in patients with relapsing‐remitting multiple sclerosis (1999) (67)
- Clinical–MRI correlations in a European trial of interferon beta-1b in secondary progressive MS (2001) (66)
- The effect of IFNβ-1b on the evolution of enhancing lesions in secondary progressive MS (2001) (66)
- Fate of neutralizing and binding antibodies to IFN beta in MS patients treated with IFN beta for 6 years (2003) (65)
- Pregnancy decision-making in women with multiple sclerosis treated with natalizumab (2018) (64)
- Intracortical excitability in patients with relapsing–remitting and secondary progressive multiple sclerosis (2009) (64)
- Natalizumab treatment in pediatric multiple sclerosis: a case report. (2009) (64)
- The Relationship between inflammation and atrophy in clinically isolated syndromes suggestive of multiple sclerosis (2004) (64)
- Testosterone amplifies excitotoxic damage of cultured oligodendrocytes (2004) (64)
- Relationship between emotional distress in caregivers and health status in persons with multiple sclerosis (2004) (63)
- The immune response to Mycobacterial 70-kDa heat shock proteins frequently involves autoreactive T cells and is quantitatively disregulated in multiple sclerosis (1996) (63)
- Visuo-proprioceptive training reduces risk of falls in patients with multiple sclerosis (2010) (62)
- Quantitative assessment of blood-brain barrier permeability in multiple sclerosis using 68-Ga-EDTA and positron emission tomography. (1988) (62)
- Supportive strategies to improve adherence to IFN beta-1b in Multiple Sclerosis — Results of the BetaPlus observational cohort study (2011) (62)
- Anti-myelin antibodies predict the clinical outcome after a first episode suggestive of MS (2007) (62)
- Interferon-β1b in the treatment of secondary progressive MS (2001) (61)
- T-lymphocyte reactivity to the recombinant mycobacterial 65- and 70-kDa heat shock proteins in multiple sclerosis. (1992) (60)
- A Controlled Trial of Mitoxantrone in Multiple Sclerosis: Serial MRI Evaluation at One Year (1994) (60)
- A Low-Cost Cognitive Rehabilitation With a Commercial Video Game Improves Sustained Attention and Executive Functions in Multiple Sclerosis (2015) (60)
- Oral contraceptives combined with interferon β in multiple sclerosis (2015) (60)
- Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b (1999) (59)
- Interferon beta failure predicted by EMA criteria or isolated MRI activity in multiple sclerosis (2014) (58)
- Patterns of Cognitive Impairment in Secondary Progressive Stable Phase of Multiple Sclerosis: Correlations with MRI Findings (2001) (58)
- Natalizumab in pediatric multiple sclerosis: results of a cohort of 55 cases (2013) (58)
- Brain reorganization during attention and memory tasks in multiple sclerosis: Insights from functional MRI studies (2006) (57)
- The Clinical Relevance of Force Platform Measures in Multiple Sclerosis: A Review (2013) (57)
- Sex hormones, brain damage and clinical course of Multiple Sclerosis (2009) (57)
- Treatment of early-onset multiple sclerosis with intramuscular interferonβ-1a: long-term results (2007) (56)
- Longitudinal evaluation of depression and anxiety in patients with clinically isolated syndrome at high risk of developing early multiple sclerosis (2003) (56)
- Advances in spinal cord imaging in multiple sclerosis (2019) (55)
- MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a (2002) (55)
- Remote Effects of Subcortical Cerebrovascular Lesions: A SPECT Cerebral Perfusion Study (1988) (55)
- The effect of Bacille Calmette-Guérin on the evolution of new enhancing lesions to hypointense T1 lesions in relapsing remitting MS (2003) (53)
- An overview of pregnancy‐related issues in patients with multiple sclerosis (2015) (53)
- Alexithymia in multiple sclerosis: relationship with fatigue and depression (2008) (53)
- Measurement of CBF and CMRO2 using the continuous inhalation of C15O2 and 15O2: Experimental validation using CO2 reactivity in the anaesthetised dog (1981) (53)
- Psychostimulant drugs increase glucose utilization in the shell of the rat nucleus accumbens. (1994) (52)
- Safety of the first dose of fingolimod for multiple sclerosis: results of an open-label clinical trial (2014) (51)
- Predictors of freedom from disease activity in natalizumab treated-patients with multiple sclerosis (2012) (51)
- Depression in the early phase of MS: influence of functional disability, cognitive impairment and brain abnormalities (1992) (50)
- The effect of interferon beta-1 b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis (2000) (50)
- Primary headache and multiple sclerosis: preliminary results of a prospective study (2008) (49)
- Pulse monthly steroids during an elective interruption of natalizumab: a post‐marketing study (2012) (49)
- MRI results from the European Study on Intravenous Immunoglobulin in Secondary Progressive Multiple Sclerosis (ESIMS) (2005) (48)
- Parity is associated with a longer time to reach irreversible disability milestones in women with multiple sclerosis (2015) (47)
- Guidelines from The Italian Neurological and Neuroradiological Societies for the use of magnetic resonance imaging in daily life clinical practice of multiple sclerosis patients (2013) (47)
- Natalizumab discontinuation and disease restart in pregnancy: a case series (2015) (47)
- Multiple Sclerosis: Changes in Thalamic Resting-State Functional Connectivity Induced by a Home-based Cognitive Rehabilitation Program. (2016) (47)
- Cannabinoid‐induced effects on the nociceptive system: A neurophysiological study in patients with secondary progressive multiple sclerosis (2009) (46)
- Does giving segmental muscle vibration alter the response to botulinum toxin injections in the treatment of spasticity in people with multiple sclerosis? A single-blind randomized controlled trial (2013) (46)
- Power spectrum analysis contribution to the detection of cardiovascular dysautonomia in multiple sclerosis (1996) (46)
- Psychosocial issue in children and adolescents with multiple sclerosis (2010) (45)
- Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study (2003) (43)
- Effect of steroids on Gd‐enhancing lesions before and during recombinant beta interferon la treatment in relapsing remitting multiple sclerosis (1998) (42)
- Mesial Temporal Cortex Hypoperfusion Is Associated With Depression in Subcortical Stroke (1994) (42)
- Functional connectivity changes and their relationship with clinical disability and white matter integrity in patients with relapsing–remitting multiple sclerosis (2015) (41)
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study) (2017) (40)
- Post-marketing survey on clinical response to interferon beta in relapsing multiple sclerosis: the Roman experience (2005) (40)
- Safety and efficacy of MD1003 (high-dose biotin) in patients with progressive multiple sclerosis (SPI2): a randomised, double-blind, placebo-controlled, phase 3 trial (2020) (40)
- No increase of serum autoantibodies during therapy with recombinant human interferon‐β1a in relapsing‐remitting multiple sclerosis (1997) (40)
- Efficacy of fingolimod and interferon beta-1b on cognitive, MRI, and clinical outcomes in relapsing–remitting multiple sclerosis: an 18-month, open-label, rater-blinded, randomised, multicentre study (the GOLDEN study) (2017) (40)
- Corticosteroids treatment (2004) (39)
- Observations during an elective interruption of natalizumab treatment: a post-marketing study (2011) (38)
- No Differences in Corpus Callosum Size by Sex and Aging (1994) (38)
- Real-world effectiveness of natalizumab and fingolimod compared with self-injectable drugs in non-responders and in treatment-naïve patients with multiple sclerosis (2017) (37)
- Three years of experience: the Italian registry and safety data update (2010) (37)
- Prevalence of multiple sclerosis in the Lazio region, Italy: use of an algorithm based on health information systems (2016) (37)
- Balance deficit with opened or closed eyes reveals involvement of different structures of the central nervous system in multiple sclerosis (2014) (36)
- Relationship between corpus callosum atrophy and cerebral metabolic asymmetries in multiple sclerosis (1992) (36)
- MRI measures and their relations with clinical disability in relapsing-remitting and secondary progressive multiple sclerosis (1997) (36)
- Disease-modifying drugs can reduce disability progression in relapsing multiple sclerosis. (2020) (35)
- 2017 revisions of McDonald criteria shorten the time to diagnosis of multiple sclerosis in clinically isolated syndromes (2018) (35)
- Remote Effects of Caudate Hemorrhage: A Clinical and Functional Study (1987) (35)
- Dentate nucleus connectivity in adult patients with multiple sclerosis: functional changes at rest and correlation with clinical features (2017) (34)
- Case Report: Multiple Sclerosis Relapses After Vaccination Against SARS-CoV2: A Series of Clinical Cases (2021) (34)
- Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis (2016) (34)
- Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group (2014) (33)
- Quality of life and depression in multiple sclerosis patients: longitudinal results of the BetaPlus study (2012) (33)
- Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study (2018) (33)
- Fingolimod vs dimethyl fumarate in multiple sclerosis (2018) (32)
- Survey of diagnostic and treatment practices for multiple sclerosis in Europe (2017) (32)
- Safety and Tolerability in Relapsing-Remitting Multiple Sclerosis Patients Treated With High-Dose Subcutaneous Interferon-Beta by Rebiject Autoinjection Over a 1-Year Period: The CoSa Study (2008) (31)
- Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study (2014) (31)
- Serum amyloid A protein is elevated in relapsing–remitting multiple sclerosis (1998) (30)
- Natalizumab treatment in multiple sclerosis: the experience of S. Andrea MS Centre in Rome (2010) (30)
- Prognostic indicators in pediatric clinically isolated syndrome (2017) (30)
- Neutralizing antibodies explain the poor clinical response to Interferon beta in a small proportion of patients with Multiple Sclerosis: a retrospective study (2009) (30)
- Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach (2017) (30)
- Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice (2013) (29)
- Investigating the phenomenon of "cognitive-motor interference" in multiple sclerosis by means of dual-task posturography. (2015) (29)
- Long-term disability trajectories in relapsing multiple sclerosis patients treated with early intensive or escalation treatment strategies (2021) (29)
- Interferon-β-1a in relapsing-remitting multiple sclerosis: effect on hypointense lesion volume on T1 weighted images (1999) (29)
- Serum elements and oxidative status in clinically isolated syndromes (2011) (28)
- The effect of inflammation and its reduction on brain plasticity in multiple sclerosis: MRI evidence (2016) (28)
- Post-marketing of disease modifying drugs in multiple sclerosis: An exploratory analysis of gender effect in interferon beta treatment (2009) (28)
- Interscanner variation in brain MR lesion load measurements in multiple sclerosis using conventional spin-echo, rapid relaxation-enhanced, and fast-FLAIR sequences. (1999) (28)
- Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy (2016) (28)
- Sex hormones: a role in the control of multiple sclerosis? (2006) (27)
- Mood and coping in clinically isolated syndrome and multiple sclerosis (2014) (27)
- Monthly brain magnetic resonance imaging scans in patients with clinically isolated syndrome (2005) (27)
- The distribution of magnetic resonance imaging response to interferonβ–1b in multiple sclerosis (2005) (27)
- The cognitive reserve theory in the setting of pediatric-onset multiple sclerosis (2013) (26)
- Clinical and MRI assessment of disease activity in patients with multiple sclerosis after influenza vaccination (1995) (26)
- Natalizumab discontinuation in patients with multiple sclerosis: Profiling risk and benefits at therapeutic crossroads (2015) (26)
- Intra-observer, inter-observer and inter-scanner variations in brain MRI volume measurements in multiple sclerosis (2001) (26)
- TRACKING OF INDIUM‐111‐OXINE LABELLED LYMPHOCYTES IN AUTOIMMUNE THYROID DISEASE (1983) (26)
- Comparable efficacy and safety of dimethyl fumarate and teriflunomide treatment in Relapsing-Remitting Multiple Sclerosis: an Italian real-word multicenter experience (2018) (26)
- The Impact of Interferon Beta and Natalizumab on Comorbid Migraine in Multiple Sclerosis (2012) (26)
- Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon β1a (1999) (25)
- Predicting the profile of increasing disability in multiple sclerosis (2018) (24)
- Cerebrospinal fluid isoprostanes are not related to inflammatory activity in relapsing–remitting multiple sclerosis (2004) (24)
- Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue damage and predictors of clinical course (2013) (24)
- Interferon-beta1b in the treatment of secondary progressive MS: impact on quality of life. (2001) (24)
- Epidemiology and current treatment of multiple sclerosis in Europe today. (2002) (24)
- Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension Study (2020) (24)
- Improved patient-reported health impact of multiple sclerosis: The ENABLE study of PR-fampridine (2016) (23)
- Interferon β treatment for multiple sclerosis has a graduated effect on MRI enhancing lesions according to their size and pathology (1999) (23)
- Pronounced focal and diffuse brain damage predicts short-term disease evolution in patients with clinically isolated syndrome suggestive of multiple sclerosis (2011) (22)
- Mitoxantrone treatment in multiple sclerosis: a 5‐year clinical and MRI follow‐up (2007) (22)
- No evidence for an effect on brain atrophy rate of atorvastatin add-on to interferon β1b therapy in relapsing–remitting multiple sclerosis (the ARIANNA study) (2016) (22)
- Structural brain correlates of neurologic abnormalities in multiple sclerosis. (1992) (22)
- Management of breakthrough disease in patients with multiple sclerosis: when an increasing of Interferon beta dose should be effective? (2011) (21)
- Minimal evidence of disease activity (MEDA) in relapsing-remitting multiple sclerosis (2020) (21)
- A controlled study of potential risk factors preceding exacerbation in multiple sclerosis. (1995) (21)
- Relation between functional connectivity and disability in multiple sclerosis: a non-linear model (2018) (20)
- Role of Cerebellar Dentate Functional Connectivity in Balance Deficits in Patients with Multiple Sclerosis. (2017) (20)
- Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis (2013) (20)
- Interferon beta-1b treatment does not induce autoantibodies (2005) (20)
- Sensitivity of enhanced MR in multiple sclerosis: effects of contrast dose and magnetization transfer contrast. (1998) (19)
- Relationship between Prolactin Plasma Levels and White Matter Volume in Women with Multiple Sclerosis (2015) (18)
- A lesion topography-based approach to predict the outcomes of patients with multiple sclerosis treated with Interferon Beta. (2016) (18)
- A one-year study on the pharmacodynamic profile of interferon-beta1a in MS. (2002) (17)
- Discontinuation of teriflunomide and dimethyl fumarate in a large Italian multicentre population: a 24-month real-world experience (2018) (17)
- MRI-based analysis of the natalizumab therapeutic window in multiple sclerosis (2012) (17)
- The influence of clinical relapses and steroid therapy on the development of Gd‐enhancing lesions: a longitudinal MRI study in relapsing—remitting multiple sclerosis patients (1997) (17)
- Natalizumab therapy of multiple sclerosis: recommendations of the Multiple Sclerosis Study Group—Italian Neurological Society (2011) (17)
- Advances in the treatment of relapsing—remitting multiple sclerosis — critical appraisal of fingolimod (2013) (17)
- Effect on Cognition of Estroprogestins Combined with Interferon Beta in Multiple Sclerosis: Analysis of Secondary Outcomes from a Randomised Controlled Trial (2017) (17)
- Determinants of the severity of comorbid migraine in multiple sclerosis (2012) (17)
- Calcium antagonists in ischemic stroke. (1988) (17)
- Transition to secondary progression in relapsing-onset multiple sclerosis: Definitions and risk factors (2020) (16)
- Clinical markers of therapeutic response to disease modifying drugs (2008) (16)
- Machine learning classifier to identify clinical and radiological features relevant to disability progression in multiple sclerosis (2021) (16)
- The heritage of glatiramer acetate and its use in multiple sclerosis (2016) (15)
- Microbe exposure, innate immunity and autoimmunity. (1999) (15)
- Cumulative effect of a weekly low dose of interferon beta 1a on standard and triple dose contrast-enhanced MRI from multiple sclerosis patients (1999) (15)
- Influence of nimodipine on cerebral blood flow in human cerebral ischaemia (1989) (15)
- Effect of dalfampridine on information processing speed impairment in multiple sclerosis (2019) (15)
- Positron Emission Tomography in Minor Ischemic Stroke Using Oxygen-15 Steady-State Technique (1987) (15)
- The pharmacovigilance program on natalizumab in Italy: 2 years of experience (2009) (14)
- Overview of MS Spasticity (2014) (14)
- Interferon beta treatment of MS in the daily clinical setting: a 3-year post-marketing study (2003) (14)
- Effect of unlabeled indium oxine and indium tropolone on the function of isolated human lymphocytes. (1985) (14)
- Balance worsening associated with nabiximols in multiple sclerosis (2019) (14)
- Sample size estimations for MRI-monitored trials of MS comparing new vs standard treatments (2001) (14)
- A longitudinal brain MRI study comparing the sensitivities of the conventional and a newer approach for detecting active lesions in multiple sclerosis (1998) (14)
- Down-regulation of cell-surface CD4 co-receptor expression and modulation of experimental allergic encephalomyelitis. (1997) (14)
- Assessing walking disability in multiple sclerosis.Mult Scler. 2012 Jul;18(7):914-24. doi: 10.1177/1352458512444498. Epub 2012 Apr 24. Review. (2012) (13)
- T cell response to myelin basic protein before and after treatment with interferon beta in multiple sclerosis (1999) (13)
- Alemtuzumab durably improves clinical outcomes in patients with active RRMS in the absence of continuous treatment: 7-year follow-up of CARE-MS-I patients (TOPAZ study) (2017) (13)
- HLA-DM polymorphisms do not associate with multiple sclerosis: an association study with analysis of myelin basic protein T cell specificity (1997) (13)
- Prognostic Accuracy of NEDA-3 in Long-term Outcomes of Multiple Sclerosis (2021) (13)
- Predictors of lymphocyte count recovery after dimethyl fumarate-induced lymphopenia in people with multiple sclerosis (2021) (12)
- Quality of life of multiple sclerosis patients with comorbid migraine (2011) (12)
- Interferon after 10 years in patients with multiple sclerosis (2006) (12)
- Determinants of Gd-enhanced MRI response to IFN-β-1a treatment in relapsing-remitting multiple sclerosis (1998) (12)
- Efficacy of alemtuzumab over 6 years in relapsing–remitting multiple sclerosis patients who relapsed between courses 1 and 2: Post hoc analysis of the CARE-MS studies (2019) (12)
- High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline (2017) (12)
- Oral Dalfampridine Improves Standing Balance Detected at Static Posturography in Multiple Sclerosis (2014) (12)
- HLA determinants in familial multiple sclerosis. (1992) (12)
- The use of ID migraine™ questionnaire in patients with multiple sclerosis (2011) (12)
- Determinants of botulinum toxin discontinuation in multiple sclerosis: a retrospective study (2017) (12)
- Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis (2016) (12)
- Anatomical and functional correlates of cognitive deficit in multiple sclerosis (1993) (11)
- Quantitative Assessment of Cerebral Blood Flow in Partial Epilepsy Using Xe‐133 Inhalation and SPECT (1991) (11)
- Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon beta1a. (1999) (11)
- Emerging oral drugs for multiple sclerosis (2008) (11)
- Central pontine myelinolysis: report of an asymptomatic case. (1995) (11)
- Evidence of Impaired Brain Activity Balance after Passive Sensorimotor Stimulation in Multiple Sclerosis (2013) (11)
- Baseline characteristics associated with NEDA-3 status in fingolimod-treated patients with relapsing-remitting multiple sclerosis (2017) (10)
- Relationship between bladder dysfunction and brain MRI in multiple sclerosis. (1991) (10)
- Antinuclear antibodies and MRI activity in multiple sclerosis (1998) (10)
- Prolonged-release fampridine in multiple sclerosis: clinical data and real-world experience. Report of an expert meeting (2018) (10)
- A comparison of the sensitivity of monthly unenhanced and enhanced MRI techniques in detecting new multiple sclerosis lesions (1999) (10)
- Abortion induces reactivation of inflammation in relapsing-remitting multiple sclerosis (2018) (10)
- Resting-state functional connectivity of anterior and posterior cerebellar lobes is altered in multiple sclerosis (2020) (10)
- Cognitive and brain imaging measures of multiple sclerosis. (1992) (10)
- An exploratory study on interferon beta dose effect in reducing size of enhancing lesions in multiple sclerosis (2007) (9)
- Multiple Sclerosis Treatment and Melanoma Development (2020) (9)
- Pregnancy in multiple sclerosis women with relapses in the year before conception increases the risk of long-term disability worsening (2021) (9)
- Global immune disregulation in multiple sclerosis: from the adaptive response to the innate immunity (2000) (9)
- Subclinical peripheral nervous system involvement in multiple sclerosis. (1995) (9)
- Multi-scale resting state functional reorganization in response to multiple sclerosis damage (2020) (9)
- Crossed quadrant homonymous hemianopsia in a case of multiple sclerosis (1995) (9)
- Impact of early diagnosis on clinical characteristics of an Italian sample of people with multiple sclerosis recruited online. (2019) (9)
- A Comprehensive Approach to Disentangle the Effect of Cerebellar Damage on Physical Disability in Multiple Sclerosis (2020) (9)
- A matter of atrophy: differential impact of brain and spine damage on disability worsening in multiple sclerosis (2021) (9)
- Acetazolamide effects on cerebral blood flow in acute reversible ischemia (1989) (9)
- Cognitive fatigability is a quantifiable distinct phenomenon in multiple sclerosis. (2019) (8)
- Emerging oral treatments in multiple sclerosis – clinical utility of cladribine tablets (2010) (8)
- Survey of diagnostic and treatment practices for multiple sclerosis (MS) in Europe. Part 2: Progressive MS, paediatric MS, pregnancy and general management (2018) (8)
- Far transfer effect associated with video game balance training in multiple sclerosis: from balance to cognition? (2015) (8)
- Facts and Trends in Cerebral Blood Flow and Metabolism: Synopsis of Brain '89 (1989) (8)
- Retraction Note: Cognitive deficits in multiple sclerosis: a review of functional MRI studies (2010) (8)
- The influence of physiotherapy intervention on patients with multiple sclerosis–related spasticity treated with nabiximols (THC:CBD oromucosal spray) (2019) (8)
- Effectiveness of fingolimod in real-world relapsing-remitting multiple sclerosis Italian patients: the GENIUS study (2020) (8)
- Functional Connectivity Changes After Initial Treatment With Fingolimod in Multiple Sclerosis (2019) (8)
- Interferon-beta-1a treatment has a positive effect on quality of life of relapsing–remitting multiple sclerosis: Results from a longitudinal study (2014) (8)
- Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis: a cross-sectional and longitudinal fMRI study (2011) (8)
- Scoring the 10‐year risk of ambulatory disability in multiple sclerosis: the RoAD score (2021) (8)
- Heat Shock Proteins and Multiple Sclerosis (1999) (8)
- Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS (2019) (7)
- Satellite potentials on EMG: Neurophysiologic evidence of axonal transection in MS? (2001) (7)
- Long-term Follow-up of the Safety of Delayed-Release Dimethyl Fumarate in RRMS: Interim Results from the ENDORSE Extension Study. (P7.235) (2015) (7)
- Contrast-enhanced magnetic resonance activity in relapsing remitting multiple sclerosis patients: a short term natural history study (2000) (7)
- Emerging oral drugs for multiple sclerosis. (2008) (7)
- Real time PCR for detection of Chlamydophila pneumoniae in peripheral blood mononuclear cells of patients with multiple sclerosis (2007) (7)
- Sustained disability improvement is associated with T1 lesion volume shrinkage in natalizumab-treated patients with multiple sclerosis (2014) (7)
- Pharmacological methods to overcome IFN-β antibody formation in the treatment of multiple sclerosis (2003) (7)
- MRI of spinal cord in MS. (2000) (6)
- The Use of Immunosuppressant Therapy for Multiple Sclerosis in Italy: A Multicenter Retroprospective Study (2016) (6)
- Sequential computed tomography and 123I-HIPDM scans in multiple sclerosis with large plaque. A case report. (1987) (6)
- The MoSt Project––More Steps in multiple sclerosis: a Delphi method consensus initiative for the evaluation of mobility management of MS patients in Italy (2014) (6)
- Extratemporal herpes encephalitis during natalizumab treatment: A case report. (2016) (6)
- Lack of association between macrocytosis and multiple sclerosis. (1992) (6)
- Validation of the Italian version of the Multiple Sclerosis Intimacy and Sexuality Questionnaire-19 (2020) (6)
- Impaired Functional Connectivity Unmasked by Simple Repetitive Motor Task in Early Relapsing-Remitting Multiple Sclerosis (2015) (6)
- Diagnostic problems in “clinically definite” multiple sclerosis patients with normal CSF and multiple MRI abnormalities (1994) (6)
- Detrimental effect of indium-111 on human lymphocytes. (1984) (6)
- Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial (2019) (5)
- Treatment of multiple sclerosis-related fatigue: pharmacological and non-pharmacological approaches (2006) (5)
- Positron CT imaging of an impending stroke (2004) (5)
- MS Study Group of the Italian Neurological Society.Postpartum relapses increase the risk of disability progression in multiple sclerosis: the role of disease modifying drugs.J Neurol Neurosurg Psychiatry. 2014 Aug;85(8):845-50. doi: 10.1136/jnnp-2013-306054. Epub 2014 Jan 8. (2014) (5)
- Letters to te editor (1995) (5)
- Assessing the Neurophysiological Effects of Cannabinoids on Spasticity in Multiple Sclerosis (2015) (5)
- Antinuclear antibodies and response to IFNβ-1a therapy in relapsing-remitting multiple sclerosis (2000) (5)
- Early use of high-efficacy disease‑modifying therapies makes the difference in people with multiple sclerosis: an expert opinion (2022) (5)
- Alemtuzumab improves clinical and MRI disease activity outcomes, including slowing of brain volume loss, in RRMS patients: 8-year follow-up of CARE-MS II (Topaz Study) (2019) (5)
- Identifying Relapses in Multiple Sclerosis Patients through Administrative Data: A Validation Study in the Lazio Region, Italy (2017) (5)
- Predictors of Cladribine Effectiveness and Safety in Multiple Sclerosis: A Real-World, Multicenter, 2-Year Follow-Up Study (2022) (5)
- Therapeutic recommendations and seasonal influenza vaccine for multiple sclerosis patients in treatment with ocrelizumab: an expert consensus (2021) (5)
- Cerebral energy relationships in dementia: a prospective study with positron emission tomography. (1982) (5)
- Haemodynamics and oxygen metabolism in patients after reversible ischaemic attack or minor ischaemic stroke assessed with positron emission tomography (2004) (5)
- Pregnancy and Fetal Outcomes after In Utero Exposure to Natalizumab in Patients with Multiple Sclerosis: A Prospective, Nation-Wide, Controlled Study (S24.006) (2016) (4)
- From High- to Low-Frequency Administered Interferon-Beta for Multiple Sclerosis: A Multicenter Study (2014) (4)
- The Prevalence of Multiple Sclerosis in the Metropolitan Area of Rome: A Capture-Recapture Analysis (2018) (4)
- Alemtuzumab outcomes by age: Post hoc analysis from the randomized CARE-MS studies over 8 years. (2020) (4)
- Influenza immunization in multiple sclerosis (1997) (4)
- High-dose contrast-enhanced MRI in multiple sclerosis. (1996) (4)
- 2014 Joint ACTRIMS-ECTRIMS Meeting (MSBoston 2014): Oral Presentations (2014) (4)
- Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in RRMS Patients Over 8 Years: CARE-MS I Follow-up (TOPAZ Study) (2019) (4)
- Cost-Effectiveness Analysis of Cannabinoid Oromucosal Spray Use for the Management of Spasticity in Subjects with Multiple Sclerosis (2020) (4)
- MS Study Group of the Italian Neurological Society.Paternal therapy with disease modifying drugs in multiple sclerosis and pregnancy outcomes: a prospective observational multicentric study.BMC Neurol. 2014 May 26;14:114. doi: 10.1186/1471-2377-14-114. (2014) (4)
- Effects of the Bacillus Calmette-Guérin (BCG) Vaccine in the Demyelinating Disease of the Central Nervous System (2014) (4)
- Alemtuzumab Controlled Clinical and MRI Outcomes and Slowed Brain Volume Loss in RRMS Patients: 8-Year Follow-up of CARE-MS II Patients (TOPAZ study) (2019) (4)
- Long-term follow-up (up to 11 years) of an Italian pediatric MS cohort treated with Natalizumab: a multicenter, observational study (2022) (4)
- Systemic hypertension as a treatable risk factor for cerebrovascular disease. (1989) (4)
- Effect of Dimethyl Fumarate vs Interferon β-1a in Patients With Pediatric-Onset Multiple Sclerosis (2022) (3)
- Teriflunomide Multiple Sclerosis Oral (TEMSO) Trial Group.Magnetic resonance imaging outcomes from a phase III trial of teriflunomide.Mult Scler. 2013 Sep;19(10):1310-9. doi: 10.1177/1352458513475723. Epub 2013 Feb 27. (2013) (3)
- Erratum to: Guidelines on the clinical use for the detection of neutralizing antibodies (NAbs) to IFN beta in multiple sclerosis therapy: report from the Italian Multiple Sclerosis Study group (2014) (3)
- The clinical value of Coop/Wonca charts in assessment of HRQoL in a large cohort of relapsing-remitting multiple sclerosis patients: Results of a multicenter study. (2017) (3)
- Multiple Sclerosis Perspective (2001) (3)
- Pregnancy does not prevent disease re-activation after natalizumab suspension in patients with multiple sclerosis (2015) (3)
- Durable Clinical Outcomes With Alemtuzumab in Patients With Active RRMS in the Absence of Continuous Treatment: 7-Year Follow-up of CARE-MS II Patients (TOPAZ Study) (P6.369) (2018) (3)
- Homing and circulation of indium-111-labelled leucocytes. A post-mortem study. (1985) (3)
- Transcranial Doppler Ultrasonography and Single Photon Emission Tomography following Cerebral Infarction (1993) (3)
- Relationship between sex hormones and MRI activity in relapsing-remitting Multiple Sclerosis (2001) (3)
- RETRACTED ARTICLE: Cognitive deficits in multiple sclerosis: a review of functional MRI studies (2010) (3)
- Effect of Interferon Beta 1a on MRI brain volume in relapsing remitting multiple sclerosis (1999) (3)
- Erratum: A multi-centre longitudinal study comparing the sensitivity of monthly MRI after standard and triple dose gadolinium-DTPA for monitoring disease activity in multiple sclerosis. Implications for phase II clinical trials (Brain, Journal of Neurology (1998) 121, Part 10) (1998) (3)
- A Combined Radiomics and Machine Learning Approach to Overcome the Clinicoradiologic Paradox in Multiple Sclerosis (2021) (3)
- Corrigendum to “Computer-aided retraining of memory and attention in people with multiple sclerosis: a randomized, double-blind controlled trial” [J. Neurol. Sci. 222 (2004) 99–104] (2004) (3)
- FP39-WE-05 High incidence of acute leukaemia in multiple sclerosis patients treated with mitoxantrone: a retrospective multicentre Italian study (2009) (3)
- Drug Holiday of Interferon Beta 1b in Multiple Sclerosis: A Pilot, Randomized, Single Blind Study of Non-inferiority (2019) (3)
- Coping and Multiple Sclerosis (2015) (3)
- Efficacy Outcome Measures of Oral Ponesimod Compared to Teriflunomide in Patients with Relapsing Multiple Sclerosis: Results of the Randomized, Active-Controlled, Double-Blind, Parallel-Group Phase 3 OPTIMUM Study (3972) (2020) (3)
- Treating multiple sclerosis with fingolimod or intramuscular interferon (2010) (3)
- The introduction of new medications in pediatric multiple sclerosis: Open issues and challenges (2020) (3)
- Natalizumab treatment and pregnancy in multiple sclerosis: A reappraisal of maternal and infant outcomes after 6 years (2022) (3)
- Risk of multiple sclerosis relapses when switching from fingolimod to cell-depleting agents: the role of washout duration (2021) (3)
- Exposure to natalizumab throughout pregnancy: effectiveness and safety in an Italian cohort of women with multiple sclerosis (2022) (3)
- Interferon beta-16 delays progression of disability in secondary progressive multiple sclerosis — results of the european multicenter study (1998) (2)
- Dynamics of the autoimmune T-cell repertoire in experimental allergic encephalomyelitis and in multiple sclerosis. (1994) (2)
- Anti-SARS-CoV-2 vaccination in people with multiple sclerosis: Lessons learnt a year in (2022) (2)
- Efficacy and Safety of 2 Doses of Ponesimod (10 and 20 mg o.d.): Interim Analysis of a Phase II Extension Trial in Relapsing-remitting Multiple Sclerosis (P3.398) (2018) (2)
- 4-31-17 MRI protocol for the European trial of beta interferon-1b in secondary progressive multiple sclerosis (1997) (2)
- Are Neurophysiological Biomarkers Able to Discriminate Multiple Sclerosis Clinical Subtypes? (2022) (2)
- Advances in preventing adverse events during monoclonal antibody management of multiple sclerosis (2019) (2)
- Memory and executive functions in healthy subjects and patients with multiple sclerosis: the role of PET and SPECT (1998) (2)
- Alemtuzumab Improves Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Relapsing-remitting Multiple Sclerosis Patients Over 8 Years: Care-MS Ii Follow-up (topaz Study) (2018) (2)
- Long-Term Efficacy, Safety and Tolerability of Ponesimod in Patients with Relapsing–Remitting Multiple Sclerosis (P01.156) (2013) (2)
- Use of Anti‐Interferon Beta Antibody Measurements in Multiple Sclerosis (2010) (2)
- Role of a baseline scan in predicting clinical and MRI activity of relapsing-remitting MS patients (1995) (2)
- Increased Within-Network Functional Connectivity May Predict NEDA Status in Fingolimod-Treated MS Patients (2021) (2)
- Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis. (2022) (2)
- T lymphocyte response to 70-kD heat shock proteins in multiple sclerosis, in tuberculosis and in healthy individuals (1994) (2)
- Tp-Te interval predicts heart rate reduction after fingolimod administration in patients with multiple sclerosis. (2016) (2)
- What is Erythema Annulare Centrifugum? A Familial Case (2013) (2)
- Bilateral paramedian thalamic infarction: Neuropsychological and perfusional followup study. (1989) (2)
- Long-term Treatment With Ponesimod in Relapsing-Remitting Multiple Sclerosis (2022) (2)
- Italian translation and validation of fatigue symptoms and impacts questionnaire in relapsing multiple sclerosis (FSIQ-RMS) (2022) (2)
- Real world experience with Cladribine at S.Andrea Hospital of Rome (2021) (2)
- 1-31-06 Gd-enhancing lesions on MRI serial scans in patients treated with interferon beta 1a (1997) (2)
- Combining MRI activity with markers of myelin damage in clinically isolated syndrome suggestive of multiple sclerosis (2006) (2)
- MRI monitoring of cerebral atrophy during a placebo-controlled trial of interferon-beta-1b in secondary progressive multiple sclerosis (2000) (2)
- Interferon-beta-1b reduces development of T1 black holes on MRI in secondary progressive multiple sclerosis (2000) (2)
- MRI for monitoring response to preventive treatment in multiple sclerosis (2009) (1)
- Gadolinium enhanced MRI predicts clinical and MRI (2003) (1)
- Ravulizumab in Aquaporin-4-Positive Neuromyelitis Optica Spectrum Disorder. (2023) (1)
- New Concepts in Pathology and Treatment of Autoimmune Disorders (2013) (1)
- Multiple s clerosis: Changes in Microarchitecture of White Matter Tracts after Training with a Video (2014) (1)
- Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS Studies (2021) (1)
- Changes in sex-hormone pattern during interferon beta therapy in women with relapsing-remitting multiple sclerosis (2002) (1)
- Long-term Cognitive Outcomes and Socioprofessional Attainment in People With Multiple Sclerosis With Childhood Onset (2022) (1)
- Different regimen of natalizumab treatment in multiple sclerosis patients: A real world study in Italy (2019) (1)
- High-dose contrast-enhanced MRI in multiple sclerosis (2005) (1)
- Durable Efficacy of Alemtuzumab in CARE-MS II Patients With RRMS With Disease Activity (Relapse) Between Courses 1 and 2 (P5.349) (2017) (1)
- New Approaches to the Study of Cerebral Ischemia in Man Using Single Photon Labeled Indicators (1985) (1)
- SPECT study of regional cerebral perfusion in the early phase of multiple sclerosis. Relation to MRI and cognitive functions (1989) (1)
- Change in Quality of Life Outcomes with Prolonged-Release Fampridine Treatment: Interim Analysis of the ENABLE Study (P03.218) (2013) (1)
- Using personalized prognosis in the treatment of relapsing multiple sclerosis: A practical guide (2022) (1)
- Shift of multiple sclerosis onset towards older age (2022) (1)
- Disease re-activation during pregnancy after natalizumab suspension in patients with multiple sclerosis (2015) (1)
- Interferon-â-1 a in relapsing-remitting multiple sclerosis : e V ect on hypointense lesion volume on T 1 weighted images (1999) (1)
- Improved Clinical and MRI Disease Activity Outcomes, Including Slowing of Brain Volume Loss, in Alemtuzumab-Treated RRMS Patients: 8-Year Follow-up of CARE-MS I (TOPAZ Study) (2019) (1)
- Eating Hubs in Multiple Sclerosis: Exploring the Relationship Between Mediterranean Diet and Disability Status in Italy (2022) (1)
- Interferon beta-1a (2019) (1)
- Clinical trials in neurology: Are rating scales stable across European countries? (2004) (1)
- 5-11-02 A randomized trial on home care in patients with multiple sclerosis (1997) (1)
- Retrospectively acquired cohort study to evaluate the long-term impact of two different treatment strategies on disability outcomes in patients with relapsing multiple sclerosis (RE.LO.DI.MS): data from the Italian MS Register (2019) (1)
- Ocrelizumab Safety in Patients with Multiple Sclerosis: Updated Analyses with a Focus on Infusion-Related Reactions (2018) (1)
- Neural bases of motor fatigue in multiple sclerosis: A multimodal approach using neuromuscular assessment and TMS-EEG (2023) (1)
- Antiphospholipid antibodies and cerebral artery dissection: Two frequent causes of brain ischemia in young adults (1994) (1)
- Long-Term Prolonged-Release Fampridine Treatment and Health-Related Quality of Life Outcomes: Interim Results of the Enable Study (2013) (1)
- [Tecfidera® (delayed-release dimethylfumarate) in the treatment of relapsing-remitting multiple sclerosis] (2017) (1)
- Evaluation of Disability Progression in Multiple Sclerosis via Magnetic-Resonance-Based Deep Learning Techniques (2022) (1)
- PND10 - GENIUS RWE STUDY (FINGOLIMOD REAL WORLD EVIDENCE ITALIAN MULTICENTER OBSERVATIONAL STUDY IN MULTIPLE SCLEROSIS)PRELIMINARY RESULTS (2018) (1)
- Association of high dose of steroid with recombinant beta interferon therapy: Prolonged effect on Gd-enhancing lesions in relapsing remitting MS (1995) (1)
- Durable Improvements in Relapse and Disability Outcomes over 7 Years with Alemtuzumab in CARE-MS II Patients: Results from the TOPAZ Study (2018) (1)
- ACUTE CEREBRAL ISCHEMIA: PHYSIOPATHOLOGICAL ASPECTS WITH CT AND SPET (1983) (1)
- Assessment of regional cerebral reperfusion with SPECT and 123I-HIPDM in patients with EC-IC bypass. (1984) (1)
- Towards a validated definition of the clinical transition to secondary progressive multiple sclerosis: A study from the Italian MS Register (2022) (1)
- Pharmacokinetics and pharmacodynamics of natalizumab in pediatric patients with RRMS. (2019) (1)
- Association Between BKPyV Serotype I Antibody Level and Natalizumab-Associated Progressive Multifocal Leukoencephalopathy. (2017) (1)
- Do patients’ and referral centers’ characteristics influence multiple sclerosis phenotypes? Results from the Italian multiple sclerosis and related disorders register (2022) (1)
- Antinuclear antibody and response to IFNbeta-1a therapy in relasping-remitting multiple sclerosis (2000) (0)
- Abstracts from the conference lectures and discussion (2001) (0)
- No association between emotional changes and MRI activity in patients with early onset multiple sclerosis (2000) (0)
- A one-year study on the pharmacodynamic profile of interferon-&bgr;1a in MS (2002) (0)
- Contents Vol. 71, 2014 (2014) (0)
- Narrative Medicine Research to Evaluate Positive Coping Factors of People Living with MS (2020) (0)
- Bacille calmette guerin (BCG) vacclne in vfultiple sclerosis (MS): A single cross-over study (1997) (0)
- Correction to: Management of pregnancy-related issues in multiple sclerosis patients: the need for an interdisciplinary approach (2017) (0)
- Alemtuzumab Improves Clinical and Radiological Outcomes in Patients with Relapsing-remitting Multiple Sclerosis Over 8 Years: Care-MS I Follow-up (topaz Study) (2018) (0)
- Interscanner Variation in Brain MR Lesion Load Measurements in MS Using Conventional Spin-Echo, RARE and Fast FLAIR Sequences. (1999) (0)
- Correction to: Early use of high-efficacy disease-modifying therapies makes the difference in people with multiple sclerosis: an expert opinion (2022) (0)
- Positron emission tomography in vascular dementia. A study with the 0-15 inhalation technique (1982) (0)
- Adjuvant therapy with bacille calmette-guérin (bcg) vaccine in relapsing-remitting multiple sclerosis (2001) (0)
- SPECT,MRIandcognitive functions inmultiple sclerosis (2011) (0)
- 054 Disability improvement is observed in each functional system in alemtuzumab-treated patients with active RRMS: results from CARE-MS II extension (2018) (0)
- Early Treatment of Stroke in Man (1992) (0)
- Gadolinium enhanced MRIpredicts clinical and MRI disease activity inrelapsing-remitt ing (2011) (0)
- Treating multiple sclerosis with fingolimod or intramuscular (2010) (0)
- Comparative effectiveness of early intensive or escalation treatment strategies on long term disability trajectories in relapsing multiple sclerosis patients (2021) (0)
- Dalfampridine to Improve Balance in Multiple Sclerosis: Substudy from a Randomized Placebo-Controlled Trial (2019) (0)
- Alterations in resting state fMRI connectivity in multiple sclerosis and correlations with balance impairment as detected with static posturography (2013) (0)
- Interferon β-1a (2018) (0)
- Contents Vol. 3, 1993 (1993) (0)
- 47. Tc-99m hexamethylpropyleneamine photon emission scans in dementia (1987) (0)
- 3-31-15 The effect of two different doses of ricombinant interferon beta-1a on relapses and total lesion volume in relapsing-remitting multiple sclerosis over the 24 month treatment period (1997) (0)
- T Lymphocyte Response to Potential Autoantigens in Patients with Multiple Sclerosis (1994) (0)
- The Increasing Evidence Base for Cannabinoids Oromucosal Spray in MS Spasticity: Presentations of a Scientific Satellite Symposium Held in Conjunction with the 29th Congress of the European Committee for Treatment and Research in Multiple Sclerosis, Copenhagen, October 2013: Proceedings (2014) (0)
- Adjuvant therapy with BCG vaccine in multiple sclerosis (1998) (0)
- Ponesimod to treat multiple sclerosis. (2021) (0)
- stroke Mesial temporal cortex hypoperfusion is associated with depression in subcortical (2011) (0)
- Therapeutic approaches, social and family issues of Italian multiple sclerosis patients. (2013) (0)
- Potential Protective Role of Pregnancy and Breastfeeding in Delaying Onset Symptoms Related to Multiple Sclerosis (2023) (0)
- Irreversible total blindness in multiple sclerosis (1991) (0)
- Predictors of definite Multiple Sclerosis in patients with pediatric onset first demyelinating clinical attack (2014) (0)
- Cerebrovascular reactivity in multiple sclerosis is restored with reduced inflammation during immunomodulation (2022) (0)
- Multiple Sclerosis Intimacy and Sexuality Questionnaire--Italian Version (2021) (0)
- MRI involvement in relapsing remitting MS: Correlation with functional systems and EDSS (1995) (0)
- Risk of a Second Clinical Attack in Pediatric Patients with a First Demyelinating Clinical Attack Suggestive of Multiple Sclerosis (P4.024) (2015) (0)
- Clinical measures of disease activity in multiple sclerosis. (1997) (0)
- TRANSVERSAL AND LONGITUDINAL VOXELWISE WHOLE BRAIN EVALUATION IN THE EARLIEST STAGES OF MULTIPLE SCLEROSIS (2010) (0)
- INFLUENZA IMMUNIZATION IN MULTIPLE SCLEROSIS. AUTHORS' REPLY (1997) (0)
- Perspective and limits of emission tomography in cerebrovascular disorders (1987) (0)
- REGIONAL ASSESSMENT OF WM AND GM DAMAGE IN PATIENTS WITH EARLY MS : A VBM AND TBSS INVESTIGATION (2008) (0)
- Should we treat pediatric radiologically isolated syndrome? An 18-year follow-up case report (2023) (0)
- Sexual Dysfunction in People with Multiple Sclerosis: The Role of Disease Severity, Illness Perception, and Depression (2023) (0)
- Sample sizes for brain atrophy outcome measures in clinical trials for secondary progressive multiple sclerosis (2008) (0)
- Head-to-head versus therapy-change studies (2013) (0)
- Durable improvements in clinical outcomes with alemtuzumab in patients with active relapsing-remitting multiple sclerosis in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (TOPAZ study) (2018) (0)
- Sustained Disability Improvement Associated With Reduced MRI Lesion Burden In Natalizumab-Treated Patients With Multiple Sclerosis (P4.192) (2014) (0)
- Traditional hospital care versus home care for patients with MS (2000) (0)
- Evolution of demyelinizing lesions examined by serial MRI (1998) (0)
- P-53 Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: Outcomes from the phase 3 CHAMPION-NMOSD trial (2023) (0)
- Multiple Sclerosis: Back home (2010) (0)
- No increase of serum autoantibodies after short-term therapy with IFN-BETA in relafsing-remitting multiple sclerosis (1995) (0)
- 4-31-03 A comparison of CSE, fast FLAIR and enhanced T1-weighted MRI scans in the detection of active lesions in multiple sclerosis: A longitudinal study (1997) (0)
- TU-142. Finding the source of motor fatigue in Multiple Sclerosis (2022) (0)
- No Changes in Functional Connectivity After Dimethyl Fumarate Treatment in Multiple Sclerosis (2022) (0)
- Interferon-β-1a (2021) (0)
- V-delta2+ gamma/delta T cells directly recognize 70-kD heat shock proteins: relevance to MS (1996) (0)
- Serial Magnetic Resonance Imaging in Patients with a First Clinical Episode Suggestive of Multiple Sclerosis: Outline of a Research Protocol (2004) (0)
- Alexithymia, fatigue and depressive symptoms in multiple sclerosis: A longitudinal study (2006) (0)
- Gender ratio of multiple sclerosis in Italy: geographical distribution and trend over 60 years (2010) (0)
- Subject Index Vol. 3, 1993 (1993) (0)
- Alemtuzumab improves disability and quality of life outcomes over 8 years in patients with RRMS (2019) (0)
- The use of immunosuppressants in multiple sclerosis: an Italian multicentre study (2010) (0)
- Alemtuzumab improves clinical and MRI outcomes, including slowing of brain volume loss, in RRMS patients over 8 years: CARE-MS I follow-up (TOPAZ Study) (2019) (0)
- Magnetic resonanceimaging changes with recombinant humaninterferon-f la:ashort term study inrelapsing-remitt ing multiple sclerosis (2011) (0)
- Suppression of experimental allergic encephalomyelitis by pretreatment with heat shock proteins (1994) (0)
- A Case Report of Cerebral Infarction Following "Misery Perfusion" (1985) (0)
- 5-23-03 Bacille calmette guerin (BCG) vaccine in multiple sclerosis (MS): A single crossover study (1997) (0)
- LACK OF ASSOCIATION BETWEEN MACRO-CYTOSIS AND MULTIPLE SCLEROSIS (1992) (0)
- Activation of Serotonin Metabolism and BDNF Changes in Depressed Patients with Multiple Sclerosis During Interferon-Beta Therapy (2009) (0)
- Breastfeeding Is Not Related with the Risk of Post-Partum Relapses in Women with Multiple Sclerosis (2010) (0)
- Interferon-&bgr;1b in the treatment of secondary progressive MS: Impact on quality of life (2001) (0)
- Interferon-β-1a (1997) (0)
- Myelin basic protein T cell epitopes in patients with multiple sclerosis (1991) (0)
- in acute ischemic stroke Predictive value of brain perfusion single-photon emission computed tomography (2011) (0)
- A Five-Year Clinical Follow-Up Study Of Patients With Multiple Sclerosis Who Started Natalizumab (P7.215) (2014) (0)
- 044 Durable clinical efficacy of alemtuzumab in patients with active rrms in the absence of continuous treatment: 7-year follow-up of CARE-MS I patients (Topaz Study) (2018) (0)
- Long-term fingolimod treatment in two pediatric patients with multiple sclerosis (2021) (0)
- 2-31-28 Serum amyloid a (SAA) protein in increased in the serum of patients with relapsing-remitting multiple sclerosis (MS) (1997) (0)
- determinant spreading without disease progression in multiple sclerosis (1998) (0)
- Multiple Sclerosis Home-Based Balance Training Using the Wii Balance Board : A Randomized , Crossover Pilot Study in (2013) (0)
- Training-dependent plasticity and far transfer effect enhanced by Bobath rehabilitation in Multiple Sclerosis. (2022) (0)
- A longitudinal study of lymphocyte activation in multiple sclerosis (1989) (0)
- PND37 RESPONSIVENESS AND CLINICAL IMPORTANT DIFFERENCES OF THE FUNCTIONAL ASSESSMENT OF MULTIPLE SCLEROSIS: RESULTS OF A LARGE MULTINATIONAL OBSERVATION STUDY (2009) (0)
- Interferon β-1a (2018) (0)
- the profile of increasing disability in multiple sclerosis (2018) (0)
- Chapter 8. Use of Anti-Interferon Beta Antibody Measurements in Multiple Sclerosis (2008) (0)
- Grey matter microstructural and volumetric short-term changes in early relapsing and progressive MS (2012) (0)
- Pathophysiology of cognitive disorders in MS (2004) (0)
- Contents Vol. 48, 2017 (2017) (0)
- Finding the source of motor fatigue in multiple sclerosis: a transcranial magnetic stimulation - electroencephalography study (2023) (0)
- Diagnosis and treatment of progressive multiple sclerosis: A position paper (2022) (0)
- Slowing of cerebral atrophy after year 1 in a placebo-controlled trial of interferon beta 1b in secondary progressive multiple sclerosis (2007) (0)
- Neuroimaging-Methodology 4 November 1997, Tuesday (1997) (0)
- , damage and predictors of clinical course Isoprostanes in clinically isolated syndrome and early multiple sclerosis as biomarkers of tissue (2013) (0)
- MRI measures and clinical disability: A six-year follow up study in relapsing-remitting multiple sclerosis patients under interferon beta therapy (2001) (0)
- Regional Ischemia on the Periphery of Old Cerebral Infarcts: A Study with Positron Emission Tomography (1985) (0)
- A controlled study ofpotential risk factors preceding exacerbation inmultiple sclerosis (1995) (0)
- MOTOR SKILL LEARNING IN MULTIPLE SCLEROSIS (2009) (0)
- , cross-sectional and longitudinal fMRI study Impaired cortical deactivation during hand movement in the relapsing phase of multiple sclerosis : a (2011) (0)
- Efficacy Outcomes in RRMS Patients Who Switched From SC IFNB-1a in CARE-MS I and II to Alemtuzumab in the Extension Studies: 7-Year Follow-up (2020) (0)
- Dalfampridine improves slowed processing speed in multiple sclerosis patients with mild motor disability: post hoc analysis of a randomized controlled trial (2021) (0)
- PO152 Alemtuzumab efficacy in patients with relapse after course 1 (2017) (0)
- Efficacy and safety of ravulizumab in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder: outcomes from the phase 3 CHAMPION-NMOSD trial (S5.002) (2023) (0)
- Immune activation in the interface between innate immunity and adaptive response:in vitro studies and therapeutical implications (1999) (0)
- T cell primary proliferative response to antigens and mitogen in patients with multiple sclerosis: Assessment of an immunosuppressive treatment with mitoxantrone (1994) (0)
- Functional correlates of motor learning in multiple sclerosis (2009) (0)
- A longitudinal study of GD-enhancing lesions in relapsing remitting MS: Relationship between clinical relapses and steroid therapy (1995) (0)
- Pregnancy And Fetal Outcomes After Paternal Exposure To Disease Modifying Drugs For Multiple Sclerosis (P4.157) (2014) (0)
- The Ability of the 15O2 Inhalation Technique to Measure Regional Cerebral Blood Flow and Metabolism: Experimental Assessment in Dogs by Using CO2 Reactivity (1981) (0)
- Emission computed tomography in strokes. (1985) (0)
- 6. PCR analysis for HTLV-I and HTLV-II sequences in patients with multiple sclerosis (1991) (0)
- Transversal and longitudinal assessment of white matter and grey matter damage in a cohort of CIS patients (2009) (0)
- Magnetic resonance imaging changes with recombinant human interferon-f la: a short term study in relapsing-remitting multiple sclerosis (2003) (0)
- P212 Cannabinoid-induced effects on the nociceptive system: a neurophysiological study in patients with secondary progressive multiple sclerosis (2008) (0)
- Cerebral blood flow studies in patients with partial epilepsy (1988) (0)
- Safety and tolerability of fingolimod in relapsing- remitting multiple sclerosis: resuls from a large open-label clinical trials. (2014) (0)
- Angiography and Doppler-Sonography in the obstructive pathology of the carotid (1982) (0)
- Altered Blood Oxygenation Level Dependent (BOLD) Cerebrovascular Reactivity in Multiple Sclerosis: Evidence for Restoration with Immunomodulation (2021) (0)
- ORIGINAL RESEARCH Structural Brain MR Imaging Changes Associated with Obsessive-Compulsive Disorder in Patients with Multiple Sclerosis (2012) (0)
- Efficacy subgroup analyses from the phase 3 CHAMPION-NMOSD trial in adults with anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder (S5.003) (2023) (0)
- Post-stroke depression: a neuroimaging study (1992) (0)
- Relation of sensorimotor and cognitive cerebellum functional connectivity with brain structural damage in patients with multiple sclerosis and no disability (2022) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Carlo Pozzilli?
Carlo Pozzilli is affiliated with the following schools:
